Core Viewpoint - The company, Innovent Biologics (01801), has seen its stock price increase by over 5%, currently trading at HKD 90.1, following the announcement of a strategic partnership with Eli Lilly to advance global R&D in oncology and immunology [1] Group 1: Strategic Partnership - Innovent Biologics has entered into its seventh strategic collaboration with Eli Lilly, focusing on innovative drug development in oncology and immunology [1] - The agreement includes an upfront payment of USD 350 million, with potential milestone payments totaling up to approximately USD 8.5 billion based on various development, regulatory, and commercialization milestones [1] - The partnership will also allow Innovent to receive a share of sales from related products in markets outside Greater China, enhancing its revenue potential [1] Group 2: Financial Implications - The upfront payment of USD 350 million is expected to be received soon, which will effectively cover the company's future overseas clinical investments [1] - Haitong International believes that the upfront and milestone payments will strengthen Innovent's financial safety net, while the sales share will provide long-term benefits from global market growth [1] - Goldman Sachs considers the current stock price undervalued, given the high implied weighted average cost of capital (12%), and has assigned a "Buy" rating with a target price of HKD 102.85 [1] Group 3: Competitive Positioning - The collaboration focuses on oncology and immunology, which aligns with Innovent's existing core pipeline, including IBI363 (PD1/IL2) and IBI343 (CLDN18.2ADC), enhancing overall competitiveness [1]
信达生物再涨超5% 与礼来达成第七次全球战略合作 高盛指其股价被低估